Published on in Vol 9 (2024)

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/58137, first published .
Comparing Insulin Against Glucagon-Like Peptide-1 Receptor Agonists, Dipeptidyl Peptidase-4 Inhibitors, and Sodium-Glucose Cotransporter 2 Inhibitors on 5-Year Incident Heart Failure Risk for Patients With Type 2 Diabetes Mellitus: Real-World Evidence Study Using Insurance Claims

Comparing Insulin Against Glucagon-Like Peptide-1 Receptor Agonists, Dipeptidyl Peptidase-4 Inhibitors, and Sodium-Glucose Cotransporter 2 Inhibitors on 5-Year Incident Heart Failure Risk for Patients With Type 2 Diabetes Mellitus: Real-World Evidence Study Using Insurance Claims

Comparing Insulin Against Glucagon-Like Peptide-1 Receptor Agonists, Dipeptidyl Peptidase-4 Inhibitors, and Sodium-Glucose Cotransporter 2 Inhibitors on 5-Year Incident Heart Failure Risk for Patients With Type 2 Diabetes Mellitus: Real-World Evidence Study Using Insurance Claims

Xuan Wang   1 , PhD ;   Anna M Plantinga   2 , PhD ;   Xin Xiong   3 , MSc ;   Sara J Cromer   4 , MD ;   Clara-Lea Bonzel   5 , MSc ;   Vidul Panickan   5 , MSc ;   Rui Duan   3 , PhD ;   Jue Hou   6 , PhD ;   Tianxi Cai   3 , PhD

1 Department of Population Health Sciences, University of Utah, Salt Lake City, UT, United States

2 Department of Mathematics and Statistics, Williams College, Williamstown, MA, United States

3 Department of Biostatistics, Harvard University, Boston, MA, United States

4 Department of Medicine, Massachusetts General Hospital, Boston, MA, United States

5 Department of Biomedical Informatics, Harvard University, Boston, MA, United States

6 Department of Biostatistics, University of Minnesota, Minneapolis, MN, United States

Corresponding Author: